Summary Safety Review - SGLT2 Inhibitors (canagliflozin, dapagliflozin, empagliflozin) - Assessing the Risk of the Body Producing High Levels of Acids in the Blood (diabetic ketoacidosis)

Ketones are a type of waste product that the body creates when it breaks down fat to use for energy. If ketones begin to build up to toxic levels in the blood (a condition known as diabetic ketoacidosis) it can lead to symptoms such as difficulties in breathing, stomach pain, nausea and vomiting, confusion, tiredness, loss of appetite, and excessive thirst. It can lead to a coma in extreme cases. Diabetic ketoacidosis can happen to anyone with diabetes but it is more common in those with type 1 diabetes, and quite rare in people with type 2 diabetes.

Data and Resources

Additional Info

Field	Value
Source
Version
Author
Author Email
Maintainer
Maintainer Email
Data Level
Agreement Required
Purpose Constraints
Redistribution Allowed
AI Training Allowed
Data Steward
Title (French)	Résumé de l'examen de l'innocuité - Inhibiteurs du SGLT2 (canagliflozine, dapagliflozine, empagliflozine) - Évaluation du risque d'acidocétose diabétique (production par l'organisme de fortes concentrations d'acides dans le sang)
Update Frequency	as_needed
Geographic Scope	[]
Criticality Level	[]
Sensitivity Level	unrestricted
Language
Contact Person
Contact Email
Data Dictionary
Open Canada Date Published	2017-05-18 00:00:00
Open Canada Date Modified
Open Canada Subject	["health_and_safety"]
Open Canada Keywords	{"fr": ["Résumé de l'examen de l'innocuité", "inhibiteurs du SGLT2", "canagliflozine", "dapagliflozine", "empagliflozine", "évaluation", "risque", "corps produisant des niveaux élevés d'acides dans le sang", "acidocétose diabétique"], "en": ["Summary Safety Review", "SGLT2 Inhibitors", "canagliflozin", "dapagliflozin", "empagliflozin", "assessing", "risk", "Body Producing High-Levels-of-Acids-in-the-Blood", "diabetic ketoacidosis"]}
Open Canada Collection	publication
Principal Organization
Reference Data
Official Source